2023
Efficacy of Oral SERDs in the treatment of ER+, HER2 - metastatic breast cancer, a stratified analysis of the ESR1 wild type and mutant subgroups
Wong N, Yap D, Ong R, Zhao J, Chan Y, Tey J, Sundar R, Lim J, Dawood S. Efficacy of Oral SERDs in the treatment of ER+, HER2 - metastatic breast cancer, a stratified analysis of the ESR1 wild type and mutant subgroups. Annals Of Oncology 2023 PMID: 37871699, DOI: 10.1016/j.annonc.2023.10.122.Peer-Reviewed Original ResearchTreatment of physician's choiceIndividual patient dataOral SERDsMetastatic breast cancerPFS benefitKaplan MeierBreast cancerEstimate time-to-event outcomesHER2- metastatic breast cancerESR1 mutation statusIndividual patient data meta-analysisOverall populationAdvanced breast cancerMeta-analysisMutant subgroupESR1 mutationsEndocrine therapyMutation statusRandomised controlled trialsOverall cohortPooled analysisDrug classesPFSPhysician's choicePreferred Reporting Items1565P ERCC1 gene polymorphism influences overall survival in early oesophageal cancer: Results from the phase III MRC OEO2 randomised controlled trial
Keogh G, Ann D, Cunningham D, Langley R, Allum W, Nankivell M, Tan P, Sundar R, Grabsch H. 1565P ERCC1 gene polymorphism influences overall survival in early oesophageal cancer: Results from the phase III MRC OEO2 randomised controlled trial. Annals Of Oncology 2023, 34: s875. DOI: 10.1016/j.annonc.2023.09.1477.Peer-Reviewed Original ResearchEarly oesophageal cancerOverall survivalRandomised controlled trialsOesophageal cancerControlled trials
2021
Personalised, Rational, Efficacy-Driven Cancer Drug Dosing via an Artificial Intelligence SystEm (PRECISE): A Protocol for the PRECISE CURATE.AI Pilot Clinical Trial
Tan B, Teo C, Tadeo X, Peng S, Soh H, Du S, Luo V, Bandla A, Sundar R, Ho D, Kee T, Blasiak A. Personalised, Rational, Efficacy-Driven Cancer Drug Dosing via an Artificial Intelligence SystEm (PRECISE): A Protocol for the PRECISE CURATE.AI Pilot Clinical Trial. Frontiers In Digital Health 2021, 3: 635524. PMID: 34713106, PMCID: PMC8521832, DOI: 10.3389/fdgth.2021.635524.Peer-Reviewed Original ResearchTumor marker levelsRandomised controlled trialsDrug dosePersonalised dosingSolid tumorsMarker levelsNational Healthcare GroupSignificant dose changesCapecitabine-based chemotherapyMetastatic solid tumorsDose of drugOpen-labelChemotherapy doseDose changesDosing recommendationsCohort expansionSingle-armSuboptimal efficacyProportion of participantsPrimary outcomeSecondary outcomesInterim analysisPhysician adherenceControlled trialsPrecision oncology